Investor Presentation

Metropolis Healthcare (MHL Group) showed strong performance, with Q4FY26 revenue up 23% YoY to ₹425 Cr and FY26 revenue at ₹1,646 Cr (+24% YoY). Profitability surged, with Q4FY26 PAT growing 75% to ₹51 Cr and FY26 PAT up 31% to ₹191 Cr.

Organic business EBITDA margins hit 27.2% in Q4. Growth is fueled by robust patient volume, higher revenue per patient, and expansion in TruHealth & Specialty segments.

MHL's "Metropolis 3.0" strategy focuses on boosting market share in core and new geographies, especially Tier 3 cities.

Digital transformation, including AI-led initiatives, is enhancing productivity and customer engagement.

Recent developments include integrating key acquisitions, expanding the service network to ~750 towns, and launching 314+ new tests in FY26, strengthening its Centre of Genomics.

Management targets mid-teen revenue CAGR (FY23-FY26) and pre-Covid margin levels, aiming to be the fastest-growing national diagnostics chain. #Diagnostics #Healthcare #Investing